Record Net Revenues of $47.5 Million, Up 211% Year-over-Year
Record Net Income of $12.5 Million, Increasing 1082% Year-over-Year
Announces Special Cash Dividend of $0.30 per share
Management to Host Conference Call Today at 11:00 a.m. ET
GARDEN CITY, NY, May 13, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today reported its financial and operational results for the first quarter ended March 31, 2022. The Company also announced today that its Board of Directors has declared a special cash dividend in the amount of $0.30 per share on its common stock, payable on June 3, 2022 to stockholders of record as of May 25, 2022.
First Quarter 2022 Highlights:
- Net revenue of $47.5 million for the three months ended March 31, 2022, as compared to $15.3 million for the three months ended March 31, 2021, an increase of approximately 211%.
- Net income of $12.5 million, or $0.81 per share, for the three months ended March 31, 2022, as compared to net income of $1.1 million, or $0.07 per share, for the three months ended March 31, 2021.
- Adjusted EBITDA income of $14.6 million for the three months ended March 31, 2022, as compared to adjusted EBITDA income of $2.3 million for the three months ended March 31, 2021.
- Cash, cash equivalents and marketable securities of $29.4 million and net working capital of $52.6 million at March 31, 2022.
- 377,000 diagnostics tests performed in the quarter ended March 31, 2022, as compared to 113,000 diagnostic tests performed in the quarter ended March 31, 2021.
- Paid special cash dividend of $0.30 per share on March 10, 2022.
- Retired $2 million of outstanding long term debt.
- Presented at the Planet MicroCap Showcase 2022 and the MicroCap Rodeo Winter Wonderland Best Ideas Conference.
Ted Karkus, ProPhase Lab’s Chief Executive Officer, commented, “Our entire team continues to generate phenomenal results. We reported $12.5 million in net income, which includes $3.4 million in income tax expense. Our adjusted EBITDA was even greater. While there was a significant spike in COVID-19 incidence in Q1 2021, our testing levels still significantly increased year over year for 2022, due to our extensive expansion and diversification of our customer base, including independent pharmacies, schools, concierge services in multiple states, municipal contract wins, etc. Our strong Q1 financial results reflect this growth in customers combined with more efficient operations.”
“We expect Q2 2022 to continue to produce strong year over year results. We expect to see additional waves of Covid-19 throughout the year as the BA2 sub-variant continues to mutate and as we learn more about BA4 and BA5 variants that are now spreading at an accelerated rate in other countries. For these reasons, we believe that demand for testing will continue for the foreseeable future. A significant portion of our business over the past two quarters was reimbursed by Health Resources & Services Administration (HRSA), which as of March 22, 2022 has stopped accepting claims for COVID-19 testing and treatment due to lack of sufficient funding. We have no way of knowing whether the HRSA program will be funded by the government in the future. However even without this funding, our business is still currently running up significantly year over year.”
“We are planning to expand our high complexity molecular diagnostics lab to include clinical testing in 2022. This will expand our menu to offer traditional testing (i.e., hematology, chemistry, immunoassays, coagulation, STDs, urinalysis etc.) Our offerings can also be tailored to the specific needs of research organizations and physicians. In parallel, we plan to build a genetics laboratory outfitted with industry leading Next Generation Sequencing (NGS) to perform Whole Genome Sequencing (WGS) and an array of genetic diagnostic test offerings, both clinical and for research.”
“We believe this expansion will open doors to academic institutions who have a growing demand to conduct genetic research which is at the heart of precision medicine. This is in addition to our current goals to leverage our Food, Drug and Mass distribution and infrastructure to significantly grow direct to consumer sales of genetic tests and ultimately, a large variety of diagnostic tests.
We are also in the early stages of working on the development of a broad spectrum anti-viral OTC dietary supplement as well as building a pharmaceutical division that would license and develop early stage drugs with enormous potential. I look forward to sharing more information about this in the coming months.
As of March 31, 2022, we had working capital of over $50 million. We believe that we have ample cash and working capital for all of our planned expansion for the foreseeable future,” concluded Mr. Karkus.
First Quarter 2022 Financial Results
For the three months ended March 31, 2022, net revenue was $47.5 million as compared to $15.3 million for the three months ended March 31, 2021. The increase in net revenue was the result of a $32.2 million increase in net revenue from diagnostic services and an immaterial increase in consumer products. The increase in net revenue for diagnostic services was due to increased COVID-19 testing volumes performed as a result of the Omicron variant, which emerged in early 2022. Overall diagnostic testing volume increased from 113,000 tests in the first quarter of 2021 to 377,000 tests in the first quarter of 2022.
Cost of revenues for the three months ended March 31, 2022 were $18.9 million, comprised of $16.7 million for diagnostic services and $2.2 million for consumer products. Cost of revenues for the three months ended March 31, 2021 were $6.3 million, comprised of $4.3 million for diagnostic services and $2.0 million for consumer products.
We realized a gross profit of $28.7 million for the three months ended March 31, 2022 as compared to $8.9 million for the three months ended March 31, 2021. The increase of $19.8 million was comprised of an increase of $19.8 million from diagnostic services offset by an immaterial decrease in consumer products. For the three months ended March 31, 2022 and 2021 we realized an overall gross margin of 60.3% and 58.5%, respectively. Gross margin for diagnostic services was 62.8% and 65.9% in the 2022 and 2021 comparable periods, respectively. The decrease in gross margin was principally due to increased sample collection costs and additional costs for HRSA-related testing for which revenue could not be recognized due to the termination of the HRSA uninsured program, partially offset by a decrease in cost of test materials. Gross margin for consumer products was 17.8% and 21.1% in the 2022 and 2021 comparable periods, respectively. Gross margin for consumer products have historically been influenced by fluctuations in quarter-to-quarter production volume, fixed production costs and related overhead absorption, raw ingredient costs, inventory mark to market write-downs and timing of shipments to customers.
Diagnostic services costs for the three months ended March 31, 2022 were $4.7 million compared to $3.8 million for the three months ended March 31, 2021. The increase of $0.9 million was due to increased COVID-19 testing volumes performed as a result of the Omicron variant, which emerged in early 2022, partially offset by a greater proportion of costs allocated to cost of revenues as a result of the nature of agreements with network providers.
General and administration expenses for the three months ended March 31, 2022 were $7.8 million as compared to $3.8 million for the three months ended March 31, 2021. The increase of $4.0 million in general and administration expenses was principally related to an increase in personnel expenses and professional fees associated with our diagnostic services business.
As a result of the effects described above, net income from operations for the three months ended March 31, 2022 was $12.5 million, or $0.81 per share, as compared to $1.1 million, or $0.07 per share, for the three months ended March 31, 2021. Diluted earnings per share for the three months ended March 31, 2022 and 2021 were $0.68 and $0.06, respectively.
Our aggregate cash, cash equivalents and restricted cash as of March 31, 2022 were $25.8 million as compared to $8.7 million at December 31, 2021. Our working capital was $52.6 million and $45.8 million as of March 31, 2022 and December 31, 2021, respectively. The increase of $17.1 million in our cash, cash equivalents and restricted cash for the three months ended March 31, 2022 was principally due to our proceeds from the sale of marketable debt securities of $5.3 million and $20.3 million cash provided by operating activities, offset by (i) purchases of marketable securities of $0.3 million, (ii) cash dividend payments of $4.6 million, (iii) repayment of note payable of $1.4 million, (iv) repurchase of common shares for $1.2 million, and (v) capital expenditures of $1.1 million.
Conference Call and Webcast Details
Management will host a conference call at 11:00 a.m. ET today, May 13, 2022, to review financial results and provide an update on corporate developments. Following management’s formal remarks there will be a question-and-answer session.
Participants can register for the conference call by navigating to:
https://dpregister.com/sreg/10166821/f2a3c48ce3
Please note that registered participants will receive their dial in number upon registration and may dial directly into the call without delay. Those without internet access or unable to pre-register may dial in to the conference call by calling: 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the schedule start time and ask to be joined into ProPhase Lab’s conference call.
The conference call will be broadcast live and available for replay at https://dpregister.com/sreg/10166821/f2a3c48ce3 and via the investor relations section of the Company's website at www.ProPhaseLabs.com.
A replay of the conference call will be available approximately two hours after the call ends at the above links. A telephonic replay of the call will be available and may be accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code #1033774.
About ProPhase Labs
ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase”) is a diversified diagnostics and genomics company that seeks to leverage its CLIA lab services to provide whole genome sequencing and research direct to consumers and build a genomics data base to be used for further research. The Company continues to provide traditional CLIA molecular laboratory services, including COVID-19 testing.
ProPhase Diagnostics, Inc., a wholly-owned subsidiary of ProPhase, offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including state-of-the-art polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19). Critical to COVID-19 testing, ProPhase Diagnostics provides fast turnaround times for results. ProPhase Diagnostics also offers best-in-class rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.
ProPhase Precision Medicine, Inc., a wholly-owned subsidiary of ProPhase, focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression.
ProPhase Global Healthcare, Inc., a subsidiary of ProPhase, was formed to seek to expand the Company’s SARS-CoV-2 (COVID-19) testing into other countries and to pursue additional healthcare-related initiatives.
ProPhase has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products and dietary supplements under the TK Supplements® brand and Phamaloz contract manufacturing subsidiary.
ProPhase actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products.
For more information, visit www.ProPhaseLabs.com.
Forward Looking Statements
Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including statements regarding projected financial results for the second quarter of 2022, our expectations regarding the COVID-19 pandemic, future waves of the pandemic and continued demand for diagnostic tsting, our plans to grow our diagnostic business and expand our lab services, our plans to grow our genomics businesses, build a WGS laboratory and attract academic institutions, our plans to develop a broad spectrum anti-viral OTC dietary supplement and build a pharmaceutical division, and our expectations regarding the sufficiency of our cash and working capital. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to general economic conditions, the scale, scope and duration of the COVID-19 pandemic (including variants), consumer demand for our COVID-19 testing and other lab processing services, our ability to collect payment for the diagnostic tests we deliver, including our ability to collect payment from uninsured individuals if emergency funding is not allocated to the HRSA uninsured program in the future, challenges relating to entering into and growing new business lines, the competitive environment, our failure to obtain and maintain necessary regulatory approvals, our ability to continue to ramp up our labs’ testing capacity and execute on our business plan, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements.
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
267-880-1111
investorrelations@prophaselabs.com
Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman
514-939-3989
Jboidman@renmarkfinancial.com
ProPhase Labs, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| March 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 25,807 | $ | 8,408 | ||||
| Restricted cash | - | 250 | ||||||
| Marketable debt securities, available for sale | 3,543 | 8,779 | ||||||
| Marketable equity securities, at fair value | - | 76 | ||||||
| Accounts receivable, net | 36,694 | 37,708 | ||||||
| Inventory, net | 4,680 | 4,600 | ||||||
| Prepaid expenses and other current assets | 1,831 | 1,496 | ||||||
| Total current assets | 72,555 | 61,317 | ||||||
| Property, plant and equipment, net | 6,440 | 5,947 | ||||||
| Prepaid expenses, net of current portion | 251 | 460 | ||||||
| Right-of-use asset, net | 4,319 | 4,402 | ||||||
| Intangible assets, net | 10,143 | 10,852 | ||||||
| Goodwill | 5,709 | 5,709 | ||||||
| Other assets | 248 | 608 | ||||||
| TOTAL ASSETS | $ | 99,665 | $ | 89,295 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 8,204 | $ | 7,026 | ||||
| Accrued diagnostic services | 1,012 | 1,890 | ||||||
| Accrued advertising and other allowances | 95 | 104 | ||||||
| Lease liabilities | 654 | 663 | ||||||
| Deferred revenue | 2,246 | 2,034 | ||||||
| Income tax payable | 4,285 | 1,312 | ||||||
| Other current liabilities | 3,274 | 2,495 | ||||||
| Total current liabilities | 19,770 | 15,524 | ||||||
| Non-current liabilities: | ||||||||
| Deferred revenue, net of current portion | 858 | 905 | ||||||
| Deferred tax liability | 443 | - | ||||||
| Note payable | 18 | 44 | ||||||
| Unsecured convertible promissory notes, net | 7,997 | 9,996 | ||||||
| Lease liabilities, net of current portion | 4,134 | 4,198 | ||||||
| Total non-current liabilities | 13,450 | 15,143 | ||||||
| Total liabilities | 33,220 | 30,667 | ||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| Stockholders’ equity | ||||||||
| Preferred stock authorized 1,000,000, $0.0005 par value, no shares issued and outstanding | - | - | ||||||
| Common stock authorized 50,000,000, $0.0005 par value, 15,485,900 and 15,485,900 shares outstanding, respectively | 16 | 16 | ||||||
| Additional paid-in capital | 105,634 | 104,552 | ||||||
| Retained earnings | 10,490 | 2,642 | ||||||
| Treasury stock, at cost, 17,018,846 and 16,818,846 shares, respectively | (49,557 | ) | (48,407 | ) | ||||
| Accumulated other comprehensive loss | (138 | ) | (175 | ) | ||||
| Total stockholders’ equity | 66,445 | 58,628 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 99,665 | $ | 89,295 | ||||
ProPhase Labs, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and Other Comprehensive Loss
(in thousands, except per share amounts)
(unaudited)
| For the three months ended | ||||||||
| March 31, 2022 | March 31, 2021 | |||||||
| Revenues, net | $ | 47,531 | $ | 15,271 | ||||
| Cost of revenues | 18,854 | 6,344 | ||||||
| Gross profit | 28,677 | 8,927 | ||||||
| Operating expenses: | ||||||||
| Diagnostic expenses | 4,672 | 3,809 | ||||||
| General and administration | 7,824 | 3,782 | ||||||
| Research and development | 35 | 115 | ||||||
| Total operating expenses | 12,531 | 7,706 | ||||||
| Income (loss) from operations | 16,146 | 1,221 | ||||||
| Interest income, net | 73 | 87 | ||||||
| Interest expense | (233 | ) | (251 | ) | ||||
| Change in fair value of investment securities | (76 | ) | - | |||||
| Income from operations before income taxes | 15,910 | 1,057 | ||||||
| Income tax expense | (3,416 | ) | - | |||||
| Income from operations after income taxes | 12,494 | 1,057 | ||||||
| Net income | $ | 12,494 | $ | 1,057 | ||||
| Other comprehensive loss: | ||||||||
| Unrealized gain (loss) on marketable debt securities | 37 | (11 | ) | |||||
| Total comprehensive income | $ | 12,531 | $ | 1,046 | ||||
| Earnings per share: | ||||||||
| Basic | $ | 0.81 | $ | 0.07 | ||||
| Diluted | $ | 0.68 | $ | 0.06 | ||||
| Weighted average common shares outstanding: | ||||||||
| Basic | 15,486 | 14,563 | ||||||
| Diluted | 18,740 | 18,200 | ||||||
ProPhase Labs, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
| For the three months ended | ||||||||
| March 31, 2022 | March 31, 2021 | |||||||
| Cash flows from operating activities | ||||||||
| Net income | $ | 12,494 | $ | 1,057 | ||||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||||||||
| Realized loss on marketable debt securities | 179 | 2 | ||||||
| Depreciation and amortization | 1,249 | 536 | ||||||
| Amortization of debt discount | 1 | 2 | ||||||
| Amortization on right-of-use assets | 83 | 85 | ||||||
| Gain on sale of assets | (23 | ) | - | |||||
| Stock-based compensation expense | 482 | 428 | ||||||
| Change in fair value of investment securities | 76 | - | ||||||
| Accounts receivable allowances | (924 | ) | - | |||||
| Inventory valuation reserve | 25 | - | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 1,938 | (11,178 | ) | |||||
| Inventory | (105 | ) | (12,987 | ) | ||||
| Prepaid and other assets | (126 | ) | 2,243 | |||||
| Other assets | 360 | (8 | ) | |||||
| Accounts payable and accrued expenses | 1,178 | 4,009 | ||||||
| Accrued diagnostic services | (878 | ) | - | |||||
| Deferred revenue | 165 | - | ||||||
| Deferred tax liability | 443 | - | ||||||
| Lease liabilities | (73 | ) | 101 | |||||
| Income tax payable | 2,973 | - | ||||||
| Other liabilities | 770 | 7,818 | ||||||
| Net cash provided by (used in) operating activities | 20,287 | (7,892 | ) | |||||
| Cash flows from investing activities | ||||||||
| Issuance of secured promissory note receivable | - | (1,000 | ) | |||||
| Purchase of marketable securities | (206 | ) | (2,005 | ) | ||||
| Proceeds from sale of marketable debt securities | 5,300 | 100 | ||||||
| Proceeds from dispositions of property and other assets | 85 | - | ||||||
| Capital expenditures | (1,095 | ) | (3,927 | ) | ||||
| Net cash provided by (used in) investing activities | 4,084 | (6,832 | ) | |||||
| Cash flows from financing activities | ||||||||
| Proceeds from issuance of common stock from public offering, net | - | 35,135 | ||||||
| Proceeds from issuance of common stock and warrants from private offering | - | 5,500 | ||||||
| Repayment of note payable | (1,426 | ) | - | |||||
| Repurchases of common shares | (1,150 | ) | - | |||||
| Payment of dividends | (4,646 | ) | - | |||||
| Net cash (used in) provided by financing activities | (7,222 | ) | 40,635 | |||||
| Increase in cash, cash equivalents and restricted cash | 17,149 | 25,911 | ||||||
| Cash, cash equivalents and restricted cash, at the beginning of the period | 8,658 | 6,816 | ||||||
| Cash, cash equivalents and restricted cash, at the end of the period | $ | 25,807 | $ | 32,727 | ||||
| Supplemental disclosures: | ||||||||
| Cash paid for income taxes | $ | - | $ | - | ||||
| Interest payment on the promissory notes | $ | 241 | $ | 250 | ||||
| Supplemental disclosure of non-cash investing and financing activities: | ||||||||
| Issuance of common shares for debt conversion | $ | 600 | $ | - | ||||
| Net unrealized gain (loss), investments in marketable debt securities | $ | 37 | $ | (11 | ) | |||
In an effort to provide investors with additional information regarding our results of operations as determined by accounting principles generally accepted in the United States of America (“GAAP”), we disclose certain non-GAAP financial measures. The primary non-GAAP financial measure we disclose are EBITDA and Adjusted EBITDA.
We define EBITDA as net income (loss) before net interest expense, income taxes, depreciation and amortization. Adjusted EBITDA further adjusts EBITDA by excluding acquisition costs, other non-cash items, and other unusual or non-recurring charges (as described in the table below).
We use EBITDA and Adjusted EBITDA internally to evaluate and manage the Company’s operations because we believe they provide useful supplemental information regarding the Company’s ongoing economic performance. We have chosen to provide this information to investors to enable them to perform more meaningful comparisons of operating results. The following table sets forth the reconciliations of EBITDA and Adjusted EBITDA excluding other costs to the most comparable GAAP financial measures (in thousands):
| For the three months ended | ||||||||
| March 31, 2022 | March 31, 2021 | |||||||
| GAAP net income (1) | $ | 12,494 | $ | 1,057 | ||||
| Interest, net | 160 | 164 | ||||||
| Depreciation and amortization | 1,250 | 457 | ||||||
| EBITDA | 13,904 | 1,678 | ||||||
| Share-based compensation expense | 482 | 428 | ||||||
| Non-cash rent expense (2) | 10 | 186 | ||||||
| Bad debt expense (3) | 250 | - | ||||||
| Adjusted EBITDA | $ | 14,646 | $ | 2,292 | ||||
(1) We believe that net income (loss) is the financial measure calculated and presented in accordance with GAAP that is most directly comparable to EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA measure the Company’s operating performance without regard to certain expenses. EBITDA and Adjusted EBITDA are not presentations made in accordance with GAAP and the Company’s computation of EBITDA and Adjusted EBITDA may vary from others in the industry. EBITDA and Adjusted EBITDA have important limitations as analytical tools and should not be considered in isolation or as substitutes for analysis of the Company’s results as reported under GAAP.
(2) The non-cash portion of rent, which reflects the extent to which our GAAP rent expense recognized exceeds (or is less than) our cash rent payments. For newer leases, our rent expense recognized typically exceeds our cash rent payments, while for more mature leases, rent expense recognized is typically less than our cash rent payments.
(3) Full allowance reserved related to restricted cash.
